NeoGenomics (NEO) Tops Q1 EPS by 2c, reaffirms outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- S&P 500, Dow rise on Mideast deal hopes, SpaceX's historic debut
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Oil nears two-month lows on reports of imminent US-Iran peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Super Micro Computer establishes $1.25 billion stock sale agreement
Neogenomics (NEO) PT Lowered to $21 at BTIG
May 2, 2024 5:24 AM EDTBTIG analyst Mark Massaro lowered the price target on Neogenomics (NASDAQ: NEO) to $21.00 (from $23.00) while maintaining a Buy rating.
The analyst comments "In this note, we update our NEO model following the company's Q1 call. NEO delivered a good 4% beat on the top line, delivered another quarter of positive Adj. EBITDA, and reiterated... More
